Perosphere Technologies Inc.

Massachusetts Institute of Technology

The Brigham and Women's Hospital, Inc.

Brown University

Perosphere Inc.

Fenwood Labs Inc.

Perosphere Pharmaceuticals Inc.

Bryan Laulicht

Solomon S Steiner

Sasha Bakhru

Edith Mathiowitz

Robert Samuel Langer

Jeffrey Michael Karp

Stefan Zappe

Janet Freilich

Jonah Samuel Myerberg

Zachary Kelly

Ravikumar Vasudevan

Alexander H Slocum, Jr

Omid C Farokhzad

James C Costin

Eoin D O'Cearbhaill

Robert Langer

Joshua Reineke

Daniel Cho

Lirong Chen

Xuan Jiang

Sasha H Bakhru

The present disclosure provides batteries that have a reduced risk or no risk of esophageal or gastrointestinal damage in a conductive aqueous environment, such as when accidentally swallowed. The batteries are, in some embodiments, nominally 9V, 3V or 1.5V coin or button cell-type batteries.

Safely ingestible batteries that rapidly deactivate in biological environments and methods of making same

Coagulometer

A microfluidic, chip-based assay device has been developed for measuring physical properties of an analyte (particularly, whole blood or whole blood derivatives). The technologies can be applied to measure clotting times of whole blood or blood derivatives, determine the effects of anticoagulant drugs on the kinetics of clotting/coagulation, as well as evaluate the effect of anticoagulant reversal agents. These technologies can additionally be used to optimize the dosage of anticoagulation drugs and/or their reversal agents. The assay is independent of the presence of anticoagulant; clotting is activated by exposure of the blood sample in the device to a glass (or other negatively charged material such as oxidized silicon) surface, which activates the intrinsic pathway and can be further hastened by the application of shear flow across the activating materials surface. The absence of chemical activating agents and highly controlled and reproducible micro-environment yields a point of care universal clotting assay.

Microfluidic chip-based, universal coagulation assay

A battery for use in electronic devices and which is safely ingested into a body and a related method of making the battery. The battery includes an anode, a cathode and a quantum tunneling composite coating. The quantum tunneling composite coating covers at least a portion of at least one of the anode or the cathode and provides pressure sensitive conductive properties to the battery including a compressive stress threshold for conduction. The compressive stress threshold may be greater than a pre-determined applied stress in a digestive tract of the body in order to prevent harm if the battery is ingested. The battery may include a waterproof seal that extends between the quantum tunneling composite coating and a gasket separating the anode and cathode to inhibit the battery from short circuiting in a conductive fluid below the compressive stress threshold.

Safely ingestible batteries and methods

Methods and compositions for securing to and removing adhesive tapes from substrates, e.g., delicate substrates such as skin, are described. The methods include providing an adhesive tape comprising an adhesive layer and a support layer in contact with the adhesive layer. A first adhesion level between the adhesive layer and the support layer is, or can be controlled to be, less than a second adhesion level between the adhesive layer and the substrate. The methods further include applying the adhesive tape to the substrate by contacting the adhesive layer to the substrate while the support layer remains in contact with the adhesive layer; and removing the support layer from the substrate by separating the support layer from the adhesive layer.

Quick-release adhesive tapes

An apparatus provides targeted placement of openings for infusing fluids into a body. The apparatus provides a driving force to a penetrating medical device, such as a needle, when the apparatus tip encounters material of high resistance. When the apparatus tip encounters a low resistance material, no further driving force is applied to the apparatus due to contraction of an element made of interlaced flexible elements. A multi-opening needle is provided in some embodiments wherein placement of one of the openings in a target region with a relatively lower external pressure allows pressurized fluid to exit the needle while openings remaining in higher pressure, non-target regions do not release substantial amounts of the fluid.

Methods and devices for inserting a needle

Methods and compositions for delivering antigens to the lymphatic system in doses that desensitize patients to future exposure to antigens have been developed. Rapid desensitization is achieved by introducing small quantities of antigen into the lymphatic system. In preferred embodiments, the compositions are administered to yield therapeutically effective levels of antigen within the lymph, where macrophages reside in the greatest concentration, by intradermal administration, using for example, microneedles or micro articles, oral administration, using for example, enteric coated capsules or tablets, or autologous transfusion. In some embodiments, the methods and compositions for delivering antigens orally achieve uptake by the Peyer's patches of the small intestines.

Methods for effectively and rapidly desensitizing allergic patients

Novel labeled compounds and metabolites thereof are disclosed, as well as pharmaceutical compositions including the compounds, and methods of using the labeled and unlabeled compounds, and specifically, 2-Amino-5-guanidino-pentanoic acid (3-{4-[3-(2-amino-5-guanidino-pentanoylamino)-propyl]-piperazin-1-yl}-propyl)-amide and metabolites thereof, for imaging, detecting and assessing disorders and diseases, such as arthritis and, more specifically, osteoarthritis by tracking proteoglycan and glycosaminoglycan content of cartilage. Also, pharmaceutical compositions comprising labeled and/or unlabeled 1,4-Bis(3-aminopropyl)piperazine are disclosed and methods of using the same.

Labeled compounds and methods of imaging, diagnosing cartilage disorders and diseases, and monitoring cartilage health using labeled and unlabeled compounds

Stabilized formulations containing a peptide, such as a glucagon, are described herein. The formulations are in the form of a solution or suspension, which exhibit little or no chemical degradation and/or aggregation of the peptide over an extended period of time. In some embodiments, the formulations are in the form of a solution containing the peptide, a solvent such as glycerin, and one or more thermal stabilizers. In other embodiments, the formulation is in the form of a suspension containing nano- and/or microparticles containing the peptide suspended in a non-aqueous, non-solvent. The nano- and/or microparticles can be prepared by micronizing the peptide with one or more humectants, such as salts, sugars, water-soluble polymers, and combinations thereof which increase the rate of dissolution of the peptide upon administration.

Stable glucagon formulations

Growing community of inventors

Danbury, CT, United States of America

Bryan Laulicht